CD38 and acute myeloid leukemia: In the context of AML, CARs with lower affinity to two potential ligands of relevance to AML, CD123 [16] and CD38 [17], have been designed and shown to have improved outcomes compared to their high-affinity counterparts; nevertheless, available data remain sparse and insufficient to establish affinity thresholds suitable for clinical translation.